The recent insider sale of ICU Medical shares at around the current price of US$104 raises caution. The absence of insider buying over the past year and the recent sale does not inspire confidence in the company despite high insider ownership.

Analysts hold steady on ICU Medical's revenue estimates and price target despite larger than expected losses. However, they anticipate a significant slowdown in the company's revenue growth, underperforming the wider industry.

The company's lower P/S ratio could be indicative of investor anticipation of less-impressive revenue performance moving forward. Some shareholders appear uneasy due to the company's weaker future prospect in terms of revenue growth.